KPC Pharmaceuticals,Inc. (SHA:600422)

Market Cap	6.33B -39.6%
Revenue (ttm)	4.55B -38.2%
Net Income	-285.36M
EPS	-0.38
Shares Out	756.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.18 (2.15%)
Ex-Dividend Date	Jul 30, 2026

Volume	9,245,600
Open	8.44
Previous Close	8.45
Day's Range	8.27 - 8.46
52-Week Range	7.45 - 14.05
Beta	-0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2026

About KPC Pharmaceuticals,Inc.

KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People’s Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections, and other products, as well as engages in the wholesale and retail of medicines and equipment. ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 5,072
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600422

Financial Performance

In 2025, KPC Pharmaceuticals,Inc.'s revenue was 6.58 billion, a decrease of -21.74% compared to the previous year's 8.40 billion. Earnings were 349.94 million, a decrease of -46.00%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error